---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-089897"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T16:31:25.992926+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Onconova reports Q2 2023 net loss of $4.3M; cash $29.7M; pipeline updates for narazaciclib and rigosertib

## Summary
- Net loss of $4.3M ($0.20 per share) vs $4.0M ($0.19) in Q2 2022.
- Cash $29.7M as of June 30, 2023; sufficient into Q2 2024.
- Topline results from Phase 1/2 narazaciclib studies expected in Q4 2023.
- Plans registrational trial for rigosertib in RDEB-SCC after constructive FDA Type B meeting in June.
- R&D expense $2.5M, G&A $2.2M for Q2 2023.

## SEC filing metadata
- accession: 0001104659-23-089897
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465923089897/0001104659-23-089897-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465923089897/tm2323468d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-089897
- JSON: https://secwatch.observer/filing/0001104659-23-089897.json
- Plain text: https://secwatch.observer/filing/0001104659-23-089897.txt

## Key facts
- Earnings Releases
  Traws Pharma, Inc. reported the quarter and six months ended June 30, 2023 results: net income $4.3 million, EPS $0.20 per share.
  - Period: the quarter and six months ended June 30, 2023
  - Net income: $4.3 million
  - EPS: $0.20 per share
  - Result: reported results
  source text: Net loss for the second quarter of 2023 was $4.3 million, or $0.20 per share on 21.0 million weighted shares outstanding, compared with a net loss of $4.0 million, or $0.19 per share for the second quarter of 2022 on 20.9 million weighted shares outstanding.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1130598/000110465923089897/0001104659-23-089897-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.